Topic
What does the evidence say for people like me?
Women, teens, older adults, type 1 diabetes, post-bariatric patients and more.
GLP-1 Drugs and Men's Health: Testosterone, Sex, Muscle and ResultsMen lose less percentage weight than women on the same dose, their testosterone tends to rise as they lose weight, the erectile function evidence points in two directions at once, and the muscle question is real. Here is what the 2025-2026 research actually found.GLP-1 Drugs for Teens: What Parents Should Know in 2026Two GLP-1 medicines are FDA-approved for adolescents with obesity, one is approved for children as young as 10 with type 2 diabetes, and none are approved under 12 for weight. Here is what the trials found, what the American Academy of Pediatrics guideline says, and what questions are still genuinely open.GLP-1s After Bariatric Surgery: What the Evidence Says in 2026Weight coming back after gastric sleeve or bypass is common, and adding semaglutide or tirzepatide is now one of the most-studied responses to it. A 2026 randomized trial and a 208,000-patient US cohort finally give real numbers - here is what they found, and what nobody has tested yet.GLP-1s and Menopause: What the Research Actually ShowsMenopause changes where your body stores fat and how much energy you burn, and GLP-1 drugs work in perimenopausal and postmenopausal women about as well as they work in younger women. The newer and more interesting question is whether menopause hormone therapy makes them work even better - here is what the evidence says, and what it does not say.GLP-1s for Type 1 Diabetes: What the Research Shows in 2026No GLP-1 or dual incretin drug is approved for type 1 diabetes anywhere, and the Wegovy label says use in type 1 diabetes has not been evaluated. But a randomized trial, a Danish national cohort and UK real-world data now exist - and they say something more specific than 'off-label.'GLP-1s Over 65: What the Data Actually ShowsNo GLP-1 label sets an age limit or an age-based dose, and trial analyses in adults 65 and older find efficacy close to younger adults. The real differences are tolerability, muscle and function, one specific fracture observation in the Wegovy label, and the fact that Medicare will not pay for weight loss.Who Should Not Take GLP-1 Drugs, According to the LabelsThe FDA labels for Wegovy, Ozempic, Zepbound and Mounjaro list exactly two absolute contraindications each. Everything else - pancreatitis, gallbladder disease, gastroparesis, pregnancy, surgery, eye disease - sits in warnings, 'not recommended' statements, and gaps where nobody has studied the question at all. Here is the actual list.